Skip to main content

Zituvio FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 26, 2023.

FDA Approved: Yes (First approved October 18, 2023)
Brand name: Zituvio
Generic name: sitagliptin
Dosage form: Tablets
Company: Zydus Pharmaceuticals (USA) Inc.
Treatment for: Diabetes, Type 2

Zituvio (sitagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

 

 

Development timeline for Zituvio

DateArticle
Oct 20, 2023Approval FDA Approves Zituvio (sitagliptin) for the Treatment of Adult Patients with Type 2 Diabetes Mellitus

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.